ASCO 2020 Bladder Cancer - Results from #20

Viewing 21-29 of 29 articles

ASCO 2020: Phase III Study of Pembrolizumab plus Chemoradiotherapy Versus Chemoradiotherapy Alone for Patients with Muscle-Invasive Bladder Cancer: KEYNOTE-992

ASCO 2020: Final Results of PEANUT: Pembrolizumab and Nanoparticle Albumin-Bound Paclitaxel as Salvage Therapy for Metastatic Urothelial Carcinoma

ASCO 2020: CheckMate 9UT: A Phase II, Randomized Study of Nivolumab, Nivolumab plus Linrodostat Mesylate, or Nivolumab plus Intravesical BCG in BCG-Unresponsive, High-Risk, NMIBC

ASCO 2020: Study EV-103: Durability Results of Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2020: From Correlation to Causation: Biomarker Development In Urothelial Cancer

ASCO 2020: Biomarker Analysis and Updated Clinical Follow-Up Of Preoperative Ipilimumab Plus Nivolumab in Stage III Urothelial Cancer (NABUCCO)

ASCO 2020: IMvigor010: Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma

ASCO 2020: DUTRENEO Trial: A Randomized Phase II Trial of DUrvalumab and TREmelimumab versus Chemotherapy as a NEOadjuvant Approach to Muscle-Invasive Bladder Cancer Patients Prospectively Selected by an Interferon-Gamma Immune Signature

ASCO 2020: Tumor Microenvironment Biomarkers Associated with Overall Survival from the Phase III IMvigor130 Study in Locally Advanced or Metastatic Urothelial Cancer

1
2